Citigroup’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Citigroup’s Portfolio LJPC Stock Details LJPC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-50,000	Closed	-$1.74M	–	7840
2017 Q3	$1.74M	Buy	+50,000	New	+$1.61M	﹤0.01%	2810

Other funds holding LJPC

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return

Kevin Tang $783 AUM 75.59% 1-Year Est. Return

Citigroup's LJPC Position: Q3 2021 in Review

Citigroup sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2021, closing a stake of 1 share.

Citigroup first reported a position in LJPC in Q1 2014 and held it in 28 quarters. The position peaked at $1.43M in Q4 2018. 54 funds tracked by Wall St. Rank hold LJPC as of Q3 2021.

Citigroup reported no remaining La Jolla Pharmaceutical Company position as of Q3 2021 after selling out during the quarter.
Citigroup sold 1 La Jolla Pharmaceutical Company share in Q3 2021.
Citigroup first reported a position in La Jolla Pharmaceutical Company in Q1 2014 and held it in 28 quarters.
Citigroup's La Jolla Pharmaceutical Company position peaked at $1.43M in Q4 2018.
54 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2021.

Based on Citigroup's 13F filing for Q3 2021, filed 10 Nov 2021.